Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.64 |
| ▸ | HTR1A | P08908 | 5/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | HTR7 | P34969 | 4/20 | 0.64 |
| ▸ | HTR6 | P50406 | 4/20 | 0.64 |
| ▸ | DRD4 | P21917 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | DRD3 | P35462 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214328 | 0.99 | DRD2 (0.65) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7214517 | 0.94 | DRD2 (0.60) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7701996 | 0.87 | DRD2 (0.49) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7214030 | 0.84 | DRD2 (0.54) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7220408 | 0.82 | DRD2 (0.53) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL7214372 | 0.81 | ADRA1D (0.58) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| Oxalic Acid SCHEMBL7214504 | 0.80 | HTR1D (0.54) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL790948 | 0.79 | DRD2 (0.72) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL5401393 | 0.79 | DRD2 (0.66) | DRD2HTR1ASLC6A4HTR7HTR6 | |
| SCHEMBL1040205 | 0.78 | DRD2 (1.00) | DRD2HTR1ASLC6A4HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| CN-1246117-A | 1, 2-indane or indoline derivatives | LUNDBECK & CO AS H (DK) | 2000-03-01 | — | — | CN | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | DRD2 14/4885HTR1A 5/4885SLC6A4 40/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | DRD2 14/4885HTR1A 5/4885SLC6A4 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.